Captrust Financial Advisors trimmed its holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 85.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,953 shares of the exchange traded fund’s stock after selling 11,101 shares during the period. Captrust Financial Advisors’ holdings in SPDR S&P Biotech ETF were worth $140,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Cranbrook Wealth Management LLC bought a new position in shares of SPDR S&P Biotech ETF in the fourth quarter valued at $26,000. Quattro Financial Advisors LLC lifted its stake in shares of SPDR S&P Biotech ETF by 49.6% in the fourth quarter. Quattro Financial Advisors LLC now owns 374 shares of the exchange traded fund’s stock valued at $31,000 after buying an additional 124 shares in the last quarter. Truewealth LLC bought a new position in shares of SPDR S&P Biotech ETF in the fourth quarter valued at $29,000. Rehmann Capital Advisory Group lifted its stake in shares of SPDR S&P Biotech ETF by 33.0% in the third quarter. Rehmann Capital Advisory Group now owns 1,435 shares of the exchange traded fund’s stock valued at $138,000 after buying an additional 356 shares in the last quarter. Finally, Proficio Capital Partners LLC bought a new position in shares of SPDR S&P Biotech ETF in the third quarter valued at $153,000.

SPDR S&P Biotech ETF stock opened at $91.27 on Friday. SPDR S&P Biotech ETF has a 1-year low of $64.38 and a 1-year high of $101.55.

TRADEMARK VIOLATION NOTICE: This piece was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://theolympiareport.com/2019/03/17/spdr-sp-biotech-etf-xbi-shares-sold-by-captrust-financial-advisors.html.

SPDR S&P Biotech ETF Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Featured Story: How to calculate compound interest

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.